
The Phase 3 study found no significant progression-free survival benefit, while its key secondary endpoint showed improved overall survival.
Amarin said a Phase 3 trial of icosapent ethyl in colorectal cancer patients undergoing liver surgery missed its primary progression-free survival endpoint, but showed improved overall survival.
In the 418-patient EMT2 trial, median progression-free survival was 13.5 months with the drug and 12.9 months with placebo. The difference was not statistically significant.
The key secondary endpoint, overall survival, favored icosapent ethyl. The estimated five-year survival rate was 62.0% with the drug and 45.1% with placebo, with an adjusted hazard ratio of 0.68 and a p-value of 0.030.
Amarin said the treatment was well tolerated, with no excess of total adverse events, bleeding, atrial fibrillation or quality-of-life deterioration. The company said it would continue working with the University of Leeds, which sponsored the trial, to assess the findings.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.